Globus Medical Class A (GMED) closed at $72.14 on November 13, 2026, down 0.2% from the previous close, on volume of 1,475,995 shares (30-day average 1,769,363).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 10, 2026 | Put Spread | 20-Nov-2675 : 80 P | 2,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Globus Medical to Participate in Jefferies Global Healthcare Conference
Globe Newswire (Mon, 9-Nov 4:02 PM ET)
Globe Newswire (Thu, 5-Nov 4:02 PM ET)
Globus Medical Acquires Synaptive Medical, Strengthening Its Position in Cranial Neurosurgery
Globe Newswire (Tue, 3-Nov 4:02 PM ET)
Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm
PRNewswire (Wed, 21-Oct 4:26 PM ET)
Globe Newswire (Wed, 14-Oct 8:00 AM ET)
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
Globe Newswire (Mon, 12-Oct 4:01 PM ET)
Globus Medical Announces CE Mark for Excelsius3D Imaging System
Globe Newswire (Thu, 3-Sep 4:30 PM ET)
Globe Newswire (Wed, 26-Aug 5:57 PM ET)
Globus Medical Expects Record 2025 Revenue, Raises 2026 Guidance Following Strong Q4 Results
Market Chameleon (Thu, 8-Jan 6:58 AM ET)
Market Chameleon (Fri, 7-Nov 5:29 AM ET)
Through innovative technology and M&A activity, Globus Medical transformed into the number two medical device manufacturer in the competitive spine market. The firm was founded in 2003 with a heavy focus on internal research and development but vaulted its market share in 2023 through a merger with former competitor NuVasive. In 2025, the company acquired Nevro, a smaller player that specialized in spinal cord stimulation therapy. Globus Medical reports two business segments, musculoskeletal solutions and enabling technologies, which consist of implants used in surgery and associated technologies that assist the physician.
Globus Medical Class A trades on the NYSE stock market under the symbol GMED.
As of November 13, 2026, GMED stock price declined to $72.14 with 1,475,995 million shares trading.
GMED has a beta of 0.20, meaning it tends to be less sensitive to market movements. GMED has a correlation of 0.00 to the broad based SPY ETF.
GMED has a market cap of $9.69 billion. This is considered a Mid Cap stock.
Last quarter Globus Medical Class A reported $764 million in Revenue and $1.23 earnings per share. This fell short of revenue expectation by $-29 million and exceeded earnings estimates by $.03.
In the last 3 years, GMED traded as high as $101.40 and as low as $44.02.
The top ETF exchange traded funds that GMED belongs to (by Net Assets): IJH, VTI, VB, VBK, VXF.
GMED has underperformed the market in the last year with a price return of -14.1% while the SPY ETF gained +13.4%. GMED has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.1% and -7.6%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
GMED support price is $70.08 and resistance is $74.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GMED shares will trade within this expected range on the day.